Dopamine D3 Receptor Occupancy in Bipolar Depression
Status:
Not yet recruiting
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
Bipolar disorder is a common condition that can cause significant disability and risk for
suicide. Second generation antipsychotic medications can be used to treat depression in
bipolar disorder, yet we do not know how they work. Here, we will use a recently approved
medication, cariprazine (Vraylar), to treat participants with bipolar depression. They will
have brain imaging with PET scans before and during treatment to understand how the
medication may be working. Particularly, we will look at the role of the D3 dopamine
receptor.